Latest News
Displaying 1 through 13 of 42 Next Page >>
| 3,500th Natural Orifice Surgery Procedure Performed at Advanced CME Course on TIF |
| February 17 , 2010 |
| Redwood City, CA (February 17, 2010) — EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today reported that the 3,500th Natural Orifice Surgery (NOS) procedure was performed in front of the over 110 surgeons from seven countries attending the first Advanced Techniques in Transoral Fundoplication CME course, held |
| EGS Reports Extension of Clinical Evidence Supporting TIF |
| January 8, 2010 |
| Redwood City, CA (January 8, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that data from two single-center series demonstrate improved clinical outcomes from a third-generation technique for its Transoral Incisionless Fundoplication (TIF) procedure. This data includes two case series |
| EGS Announces Key Patent Issued |
| December 31 , 2009 |
| Redwood City, CA (December 31, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the U.S. Patent and Trademark Office has issued a key patent covering its SerosaFuse fastener and “over the wire” delivery system. Patent no. 7,632,287, entitled "Tissue fixation devices and assemblies |
| EGS Announces Advanced Transoral Fundoplication Educational Course Initiative for 2010 |
| December 9 , 2009 |
| Redwood City, CA (December 9, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced the Advanced Techniques in Transoral Fundoplication CME course series for 2010. The first course, scheduled for January 28-29, 2010, in Denver, CO, will be directed by esteemed surgeons Reginald Bell, MD |
| EGS Announces Additional Financial Investment |
| November 25, 2009 |
| Redwood City, CA (November 25, 2009) — EndoGastric Solutions (EGS) today announced the closing of a $21.5 Million Series E financing. The funding will be used to support an expanding commercial presence for the company’s market-leading Natural Orifice Surgery (NOS) platform, which includes the EsophyX and StomaphyX surgical devices. |
| EGS Announces Initiation of Clinical Study to Demonstrate Efficacy of StomaphyX for Revisional Weight Loss Surgery |
| Monday, August 24, 2009 |
| Redwood City, CA (August 24, 2009) — EndoGastric Solutions (EGS), the recognized leader in the field of Natural Orifice Surgery (NOS), announced enrollment of the first patients in a clinical trial evaluating the use of StomaphyX to reduce weight regain in patients who have had Roux-en-Y gastric bypass surgery. The StomaphyX clinical study |
| ASGS Issues Position Statement Supporting TIF Natural Orifice Surgery for GERD |
| Thursday, July 9, 2009 |
| Redwood City, CA (July 9, 2009) – EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), announced that the American Society of General Surgeons (ASGS) has published a position statement endorsing its Transoral Incisionless Fundoplication (TIF) procedure for the treatment of GERD. ASGS is the preeminent |
| Munroe Regional Medical Center Performs 100th TIF Procedure |
| Friday, May 8, 2009 |
| Redwood City, CA (May 7, 2009) – EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Munroe Regional Medical Center, in Ocala, Florida, has performed 100 TIF (Transoral Incisionless Fundoplication) procedures for the treatment of chronic acid reflux, or gastroesophageal reflux |
| EndoGastric Solutions Finalizes Expansion of Commercial Organization |
| Friday, April 17, 2009 |
| Redwood City, CA (April 17, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced completion of an important sales and marketing expansion to support its growing commercialization success. EGS also announced the appointment of Tom Dempsey as Vice President of U.S. Sales, effective |
| SAGES Issues Position Statement Supporting Endolumenal Therapies for GERD and Obesity |
| Friday, April 10, 2009 |
| Redwood City, CA (April 10, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced its support of SAGES (the Society of American Gastrointestinal and Endoscopic Surgeons) Position Statement on Endolumenal Therapies for Gastrointestinal Diseases including GERD and Obesity published |
| Published Study Supports Two-Year Safety and Efficacy of Incisionless TIF Surgery for the Treatment of GERD |
| Thursday, March 26, 2009 |
| Redwood City, CA (March 26, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced publication of a two-year study of TIF (Transoral Incisionless Fundoplication) procedure for the surgical treatment of GERD (gastroesophageal reflux disease) confirming the procedure’s safety and |
| EndoGastric Solutions Announces Shipping Over 700 New EsophyX2 Devices |
| Friday, February 20, 2009 |
| Redwood City, CA (February 20, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that over 700 EsophyX2 devices have shipped worldwide. The next generation of its innovative EsophyX® device, EsophyX2 facilitates the creation of a robust, tight antireflux valve with the TIF®2 |
| 27 New Medical Centers Join Growing List of U.S. Sites Performing NOS EsophyX or StomaphyX Procedures |
| Wednesday, January 28, 2009 |
| Redwood City, CA (January 28, 2009) — EndoGastric Solutions® (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that 15 new U.S. medical centers performed their first TIF® (Transoral Incisionless Fundoplication) surgical procedures for the treatment of GERD (Gastroesophageal Reflux Disease) last quarter |
NP01937-01A
